Answers are grounded in this paper and cite their sources.
Cohort study analyzes treatment trends and survival outcomes in patients with primary central nervous system low-grade lymphoma, suggesting improved prognosis over two decades.
The incidence of primary central nervous system low-grade B-cell lymphoma (PCNSL-LG) is rare. We aimed to provide the first large-scale analysis of treatment modalities, survival trends, and prognostic factors for PCNSL-LG. Patient data diagnosed between 2000 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. A total of 267 adult PCNSL-LG patients were included. The year of diagnosis was divided into the time period-1 (2000-2009) and the time period-2 (2010-2021). Radiotherapy alone usage remained stable over time (27.34% vs. 30.22%, p = 0.605). Chemotherapy alone showed a modest, non-significant increase (25.00% vs. 31.66%, p = 0.229), while combined chemoradiotherapy declined significantly from 29.69% to 15.11% (p = 0.004). The 1-, 5-, and 10-year overall survival (OS) rates for all PCNSL-LG patients were 84.3%, 73.4%, and 61.8%, respectively. Overall survival improved significantly, with median OS extending from 11.25 years in period-1 to not reached in period-2 (HR 0.46, 95% CI: 0.28-0.74; p = 0.001). Surgery was associated with improved outcomes compared with non-surgical management (HR 0.47, 95% CI: 0.31-0.72, p < 0.001). In patients with MALT lymphoma histology, no significant prognostic difference was observed across treatment modalities (p = 0.838). This study underscores a marked improvement in survival among PCNSL-LG patients over the past two decades and offers valuable insights for optimizing clinical management and improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: